Dr. Peter Marks, an ex-FDA vaccine official, is warning of a fundamental change at the agency—where vaccine skepticism now ...

Private Placement: In November 2024, the Company completed a second tranche of a non-brokered private placement, issuing 231,818 units at C$0.55 per unit, raising aggregate gross proceeds of C$127 ...

Biosimilars Council’s Craig Burton predicted that only 10% of the drugs coming off patent soon will have competition.

Adalimumab had superior efficacy and safety outcomes compared with secukinumab and bimekizumab for the treatment of hidradenitis suppurativa.

In patients with RA, BMI affects cardiovascular risk, differing by anti–citrullinated protein antibody (ACPA) status and ...

Rheumatoid arthritis (RA) patients face very different risks for cardiovascular disease and events depending on their body ...

Expert Rev Pharmacoeconomics Outcomes Res. 2012;12(3):319-333. The most recent biologic therapy to receive marketing approval, tocilizumab, was evaluated in a 24-week, randomized, placebo ...

Based on clinical trial data, abatacept was not associated with increased malignancy risks in RA or PsA; observational data indicated a higher risk vs other b/tsDMARDs.

Using vedolizumab first, before tumor necrosis factor-α inhibitors, improved quality-adjusted life-years in both ulcerative ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

Several characteristics, including BMI and Charlson Comorbidity Index, were associated with super response to biologics in patients with psoriasis.

Results presented here showed the use of an allograft, autograft or no biologic adjuvant had equivalent fusion rates and rates of postoperative adverse outcomes in foot and ankle arthrodesis.“What ...